A PYMNTS Company

US: FTC orders concessions on $1.6B generic drugmaker buyout

By  |  September 29, 2013

The US Federal Trade Commission announced its approval for generic drugmaker giant Mylan to acquire Agila in a $1.6 billion deal, though the regulator will require Mylan to divest assets that make 11 drugs to quell competition concerns.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, Mylan is set to buy the India-based unit of Strides Arcolab as the US conglomerate looks to double its injectable drugs portfolio.

    The deal was first announced last February.

    Full Content: Economic Times of India

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.